Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hot Opportunities In The African Emerging Markets - A Look At South Africa (Part 1 of 2)

This article was originally published in PharmAsia News

Executive Summary

Although the fast-growing South African pharmaceutical market is dominated by local generic firms, multinational pharma companies are also seeing significant growth through new initiatives and product launches, said investment firm Credit Suisse in a September report based on IMS Health data

You may also be interested in...



Hot Opportunities In The African Emerging Markets - A Look At South Africa (Part 2 of 2)

Although the fast-growing South African pharmaceutical market is dominated by local generic firms, multinational pharma companies are also seeing significant growth through new initiatives and product launches, said investment firm Credit Suisse in a September report based on IMS Health data.

Hot Opportunities In The African Emerging Markets - A Look At South Africa (Part 2 of 2)

Although the fast-growing South African pharmaceutical market is dominated by local generic firms, multinational pharma companies are also seeing significant growth through new initiatives and product launches, said investment firm Credit Suisse in a September report based on IMS Health data.

Merck Emerging Markets President Kevin Ali On The Branded Generics Business: An Interview With PharmAsia News (Part 2 of 2)

When Merck & Co. Inc. Emerging Markets President Kevin Ali speaks of innovation, it is emblematic of Merck's deep-rooted focus on new drug discovery, but the veteran executive now sees opportunities in the differentiated, branded generics segment. On a recent visit to India, Ali spoke to PharmAsia News' India Bureau about incrementally innovative drugs, access to affordable medicines and also Merck's plans in the BRIC-MT nations.

Related Content

UsernamePublicRestriction

Register

SC076512

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel